Sage Therapeutics Inc (SAGE)
32.53
+0.70 (+2.20%)
USD |
NASDAQ |
May 20, 16:00
32.50
-0.03 (-0.09%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 1.921B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -56.12% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 303.44 |
| Price to Book Value | 1.187 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 86.51% |
News
Headline
Wire
Time (ET)
MT Newswires
05/10 12:39
MT Newswires
05/04 08:35
MT Newswires
05/04 07:59
Yahoo
05/04 06:30
MT Newswires
05/03 16:07
Yahoo
05/03 06:30
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 08/03/2022* | -- | Results | Q2 2022 | -- | -2.17 | -- | |
| 08/03/2022* | 08:00 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
| 05/03/2022 | -- | Results | Q1 2022 | -2.07 | -2.00 | -3.75% | |
| 05/03/2022 | 08:00 EST | Earnings Call | Q1 2022 | -- | -- | -- | |
| 02/24/2022 | -- | Results | Q4 2021 | -2.12 | -2.16 | 2.00% | |
| 02/24/2022 | 08:00 EST | Earnings Call | Q4 2021 | -- | -- | -- | |
| 11/02/2021 | -- | Results | Q3 2021 | -2.21 | -1.86 | -18.78% | |
| 11/02/2021 | 08:00 EST | Earnings Call | Q3 2021 | -- | -- | -- |
*Estimated Date/Time
Earnings
Profile
Edit
| Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the study of the nervous system and brain to discover medicines to treat life-threatening, rare central nervous system disorders. The company's lead development program is SAGE-217 program which is in Phase 3 clinical trials for post-partum depression, essential tremor, Parkinson's disease, and major depressive disorder. The company is also developing several other compounds for treatment that are in the early stage of development. |
| URL | http://www.sagerx.com |
| Investor Relations URL | https://investor.sagerx.com/ |
| HQ State/Province | Massachusetts |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Aug. 03, 2022 (est.) |
| Last Earnings Release | May. 03, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0.00% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of May 20, 2022.
Fundamentals
| Revenue (TTM) | 6.307M |
| Total Expenses (TTM) | 493.91M |
| Net Income (TTM) | -484.18M |
| Total Assets (Quarterly) | 1.706B |
| Total Liabilities (Quarterly) | 87.20M |
| Shareholders Equity (Quarterly) | 1.619B |
| Cash from Operations (TTM) | -376.90M |
| Cash from Investing (TTM) | -353.19M |
| Cash from Financing (TTM) | 9.51M |
Ratings
Profile
Edit
| Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the study of the nervous system and brain to discover medicines to treat life-threatening, rare central nervous system disorders. The company's lead development program is SAGE-217 program which is in Phase 3 clinical trials for post-partum depression, essential tremor, Parkinson's disease, and major depressive disorder. The company is also developing several other compounds for treatment that are in the early stage of development. |
| URL | http://www.sagerx.com |
| Investor Relations URL | https://investor.sagerx.com/ |
| HQ State/Province | Massachusetts |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Aug. 03, 2022 (est.) |
| Last Earnings Release | May. 03, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Risk Info
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Morningstar | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| SAGE Tweets |